Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Taro Pharmaceutical Industries Ltd.    TARO   IL0010827181

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Taro Pharmaceutical Industries Ltd. : Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/08/2012 | 11:25pm CET

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") announced today that it delivered a letter to one of its shareholders IsZo Capital Management LP ("IsZo") in response to IsZo's letter to Taro's Special Committee of the Board of Directors dated November 5, 2012. The full text of the letter is set forth below:

Re: Taro Rejects IsZo's FY Q2 Under Reporting Allegation as Untrue and Irresponsible

Dear Mr. Sheehy,

We at Taro are very appreciative of our shareholders' communications. More recently, our ability to respond to certain inquiries has been limited in light of the pending merger between Taro and Sun Pharma and the related shareholder meeting scheduled December 6, 2012. Rather, our management team's primary focus continues to be on Taro's core business, the performance of which speaks for itself.

Without responding to your many unfounded allegations over the past few months, I feel compelled to publicly correct one of your most recent statements. In your November 5th letter and corresponding press release, you contend that Taro is "gaming its reserves." Your allegation is simply untrue and your comment is, at a minimum, irresponsible to your fellow Taro shareholders.

As a NYSE listed company, Taro takes its financial accounting and reporting obligations very seriously. Although our quarterly financial reporting is presented on an unaudited basis, the accounting methodologies used in estimating our reserves are "consistently applied" quarter to quarter, in conformity with U.S. GAAP. Over the last couple of years, at the request of our Board and Audit Committee, we have taken an extra step by having our independent auditors perform certain "agreed upon procedures" on our financial statements focusing on specific areas, including reserves, prior to issuing our quarterly releases, including that for the quarter ended September 30, 2012.

Given your broad industry knowledge, you undoubtedly appreciate that, while IMS data is useful to the industry for general U.S. market intelligence and a general understanding of long term, product trends, it is not reliable (or prepared) for consolidated financial reporting analysis as you propose.

Finally, I recognize your excitement for Taro as expressed in your letter. I believe that all Taro shareholders have benefited tremendously at what the new management team, under the leadership of Mr. Shanghvi and, subsequently, Mr. Sundaram, have accomplished since the change in control in September 2010.

Sincerely,

/s/ Jim Kedrowski

Jim Kedrowski
Interim Chief Executive Officer

************************

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.

Taro Pharmaceutical Industries Ltd.
William J. Coote, 914-345-9001
VP, Treasurer
[email protected]


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TARO PHARMACEUTICAL INDUST
11/11 TARO PHARMACEUTICAL INDUSTRIES : Provides Results for September 30, 2017
11/08 TARO PHARMACEUTICAL INDUSTRIES : posts 2Q profit
11/08 TARO PHARMACEUTICAL INDUSTRIES : Provides Results for September 30, 2017
11/01 TARO PHARMACEUTICAL INDUSTRIES : to Announce Second Quarter Results on November ..
10/30 TARO PHARMACEUTICAL INDUSTRIES : to Announce Second Quarter Results on November ..
09/14 TARO PHARMACEUTICAL INDUSTRIES : Announces Joining of CEO
09/03 TARO PHARMACEUTICAL INDUSTRIES : Announces Joining of CEO
09/01 TARO PHARMACEUTICAL INDUSTRIES : Announces Joining of CEO
08/10 TARO PHARMACEUTICAL INDUSTRIES : to Announce First Quarter Results on August 8, ..
08/10 TARO PHARMACEUTICAL INDUSTRIES : Pain for sun scrip
More news
News from SeekingAlpha
11/09 YOUR DAILY PHARMA SCOOP : Portola Upside, Novartis Reports Positive Cosentyx Dat..
11/08 Taro Pharmaceutical Industries' (TARO) CEO Uday Vijaykumar Baldota on Q2 2018..
11/07 Taro Pharmaceutical reports Q2 results
10/26 Greenblatt's Magic Wand Must Be Broken This Year -- Magic Formula Large And M..
10/22 More Wizardry For 2017 -- Magic Formula Large Cap Strategy Update, 2017 YTD
Financials ($)
Sales 2018 792 M
EBIT 2018 432 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 11,92
P/E ratio 2019 14,17
Capi. / Sales 2018 5,79x
Capi. / Sales 2019 6,43x
Capitalization 4 586 M
Chart TARO PHARMACEUTICAL INDUST
Duration : Period :
Taro Pharmaceutical Indust Technical Analysis Chart | TARO | IL0010827181 | 4-Traders
Technical analysis trends TARO PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 100 $
Spread / Average Target -12%
EPS Revisions
Managers
NameTitle
Uday Vijaykumar Baldota Chief Executive Officer & Director
Dilip Shantilal Shanghvi Chairman
Itamar Karsenti Vice President & Operations Head-Haifa
Mariano Balaguer VP, Chief Financial & Accounting Officer
Avi Avramoff Global Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
TARO PHARMACEUTICAL INDUSTRIES LTD.7.52%4 586
JOHNSON & JOHNSON19.78%370 740
NOVARTIS11.20%219 321
PFIZER8.90%210 830
ROCHE HOLDING LTD.-1.55%200 193
MERCK AND COMPANY-6.23%150 550